Results 221 to 230 of about 35,569 (305)

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States. [PDF]

J Manag Care Spec Pharm
Ofili SC, Chen H.
europepmc   +1 more source

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of the fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin degludec plus insulin aspart (IDegAsp) according to the injection time of IDegAsp. Materials and Methods The 24‐week, multicentre, randomised, open‐label Soli‐D study enrolled Chinese adults ...
Xin Li, Juan Wang, Tong Liu, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Lei Kang, Qin Du, Ming Liu   +8 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist use and clinical outcomes after lung transplantation: A single-center cohort study. [PDF]

JHLT Open
Miyashita Y, Kaiho T, Reichenbach R, Yagi Y, Arunachalam A, Kurihara C.   +5 more
europepmc   +1 more source

Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross‐Sectional Population‐Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Chronic kidney disease (CKD) is a common complication of Type 2 diabetes that frequently co‐occurs with cardiovascular disease. We aimed to characterise CKD in adults with Type 2 diabetes, quantify its prevalence across severity levels and examine pharmacological treatment patterns and healthcare utilisation.
Neora Alterman, Yoel Toledano, Noga Fallach, Victor Gross, Galia Zacay   +4 more
wiley   +1 more source

Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy

American Journal of Preventive Cardiology
Harshvir S. Bal, Amrita Nayak, Akhil Pampana, Sindhoosha Malay, Astha Upadhyaya, Nehal Vekariya, Garima Arora, Pankaj Arora   +7 more
doaj   +1 more source

Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis. [PDF]

ACG Case Rep J
Guralwar C, Mitsuhashi S, Ashkar M, Chedid VG.   +3 more
europepmc   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report. [PDF]

Case Rep Surg
Canali G, Herfeld G, Averous G, Baltzinger P, Addeo P.   +4 more
europepmc   +1 more source

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin, Milana Ivkovic, Inger Smith, Naveen Rathor, Rohan Chowdhury, Alexander Hodkinson, Robert F. Kushner   +6 more
wiley   +1 more source